Patents Assigned to Fertin Pharma A/S
  • Patent number: 12194149
    Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
    Type: Grant
    Filed: September 11, 2023
    Date of Patent: January 14, 2025
    Assignee: Fertin Pharma A/S
    Inventors: Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen
  • Publication number: 20250009663
    Abstract: A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 9, 2025
    Applicant: Fertin Pharma A/S
    Inventors: Helle Wittorff, Christine Nøhr Pedersen
  • Publication number: 20250009650
    Abstract: A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.
    Type: Application
    Filed: July 8, 2024
    Publication date: January 9, 2025
    Applicant: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Publication number: 20250009767
    Abstract: An adhesive oral disc for sustained release of cannabinoids is presented. The disc includes one or more cannabinoids and is composed of at least a mucosal contacting layer having a mucosal contacting surface operable to be fixed to the gingiva of a person in need of alleviation or treatment of a medical condition, where the mucosal contacting layer includes one or more mucoadhesive polymers allowing the adhesive oral disc to adhere to the gingiva for an extended period of time. Further, the disc includes a non-mucoadhesive module fused to the mucosal contacting layer, where the non-mucoadhesive module includes a solid tablet composition allowing the non-mucoadhesive module to dissolve within an extended period of time upon adhesion of the adhesive oral disc to the gingiva. The invention is particularly useful for alleviation or treatment of ulcers.
    Type: Application
    Filed: July 8, 2024
    Publication date: January 9, 2025
    Applicant: Fertin Pharma A/S
    Inventors: Helle Wittorff, Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Gordon Findlay Dawson
  • Publication number: 20240415853
    Abstract: An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors.
    Type: Application
    Filed: March 21, 2024
    Publication date: December 19, 2024
    Applicant: Fertin Pharma A/S
    Inventors: Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
  • Publication number: 20240415775
    Abstract: An oral chewable tablet contains dextrose in an amount from 50 to 95% by weight of the tablet; and one or more active ingredients in an amount from 0.1 to 50% by weight of the tablet. The oral chewable tablet includes at least two compressed layers containing the dextrose and the one or more active ingredients, the first of the compressed layers being cohered to and adjacent to the second layer.
    Type: Application
    Filed: October 12, 2022
    Publication date: December 19, 2024
    Applicant: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Patent number: 12156943
    Abstract: The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 3, 2024
    Assignee: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Patent number: 12128138
    Abstract: A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: October 29, 2024
    Assignee: Fertin Pharma A/S
    Inventors: Helle Wittorff, Christine Nøhr Pedersen
  • Publication number: 20240350404
    Abstract: An orally dissolvable or chewable tableted powder formulation, includes one or more mesoporous silica carriers loaded with a liquid cannabinoid suspension or solution; one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation; and one or more flavors, wherein the liquid cannabinoid suspension or solution includes one or more cannabinoids and one or more non-volatile solvents in a weight ratio of cannabinoid to solvent of 10:1 to 1:10.
    Type: Application
    Filed: March 21, 2024
    Publication date: October 24, 2024
    Applicant: Fertin Pharma A/S
    Inventors: Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
  • Patent number: 12115155
    Abstract: The invention relates to an oral nicotine formulation for use in the alleviation of nicotine craving, the formulation comprising a content of nicotine and a content of a pH regulating agent, wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 7.5 during the first 120 seconds upon oral administration.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 15, 2024
    Assignee: Fertin Pharma A/S
    Inventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
  • Patent number: 12109312
    Abstract: An oral tablet for taste masking of active ingredients includes a population of particles and an active ingredient with off-note taste. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: October 8, 2024
    Assignee: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Patent number: 12102714
    Abstract: A disintegrating oral tablet suitable for active pharmaceutical ingredients includes a population of particles and at least one flavor ingredient. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: October 1, 2024
    Assignee: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Publication number: 20240316077
    Abstract: An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.
    Type: Application
    Filed: March 21, 2024
    Publication date: September 26, 2024
    Applicant: Fertin Pharma A/S
    Inventors: Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
  • Publication number: 20240285610
    Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.
    Type: Application
    Filed: April 29, 2024
    Publication date: August 29, 2024
    Applicant: Fertin Pharma A/S
    Inventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
  • Patent number: 12005058
    Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: June 11, 2024
    Assignee: FERTIN PHARMA A/S
    Inventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
  • Patent number: 11911375
    Abstract: A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine-ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: February 27, 2024
    Assignee: FERTIN PHARMA A/S
    Inventors: Kent Albin Nielsen, Jessie Poulsen
  • Publication number: 20240000706
    Abstract: A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.
    Type: Application
    Filed: August 3, 2023
    Publication date: January 4, 2024
    Applicant: Fertin Pharma A/S
    Inventors: Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen, Kent Albin Nielsen, Rikke Pranger-Rasmussen
  • Publication number: 20240000713
    Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 4, 2024
    Applicant: Fertin Pharma A/S
    Inventors: Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen
  • Publication number: 20230346768
    Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.
    Type: Application
    Filed: July 7, 2023
    Publication date: November 2, 2023
    Applicant: Fertin Pharma A/S
    Inventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
  • Patent number: 11786473
    Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: October 17, 2023
    Assignee: Fertin Pharma A/S
    Inventors: Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen